Pramlintide

Limits on what this shows

• Key negative/null findings: None identified; only one drug-specific mitochondrial study was located.
• At-risk subgroups: Not established; the only human-cell evidence is disease-model (intervertebral disc) tissue, not a general population finding.

Regulatory status

Not addressed in the FDA label.

Population evidence

Wu X et al., "Pramlintide regulation of extracellular matrix (ECM) and apoptosis through mitochondrial-dependent pathways in human nucleus pulposus cells," Int J Immunopathol Pharmacol, 2018, PMID 29256292: human cell (nucleus pulposus) study, pramlintide specifically tested. Confirmed via PubMed search-listing page (title, journal, year, PMID, and a brief listing-page note indicating the study examined pramlintide's effect on cell viability, calcium concentration, and mitochondrial membrane potential); the full abstract page returned a bot-verification challenge on every attempt this session (5 attempts across the review, spaced up to 90 seconds apart) and could not be read.

Mechanism

Named at the category level only: the study title states pramlintide acts "through mitochondrial-dependent pathways" affecting apoptosis and ECM regulation. Which direction (mitochondrial protection versus mitochondrial injury) and which specific markers moved could not be confirmed this session.

Counter-evidence held on record

No other pramlintide-specific mitochondrial study was found to corroborate or contradict this one; it stands alone. This entry is graded yellow on the confirmed existence of a drug-specific mitochondrial-pathway interaction, not on a confirmed direction of harm or benefit. It must not be read as evidence that pramlintide damages or protects mitochondria in general use; a future revision should re-attempt full-text access to resolve the direction.

Limits on what this shows

• Key negative/null findings: None identified; searches did not surface a study reporting pramlintide worsening oxidative-stress markers.
• At-risk subgroups: Not applicable (protective direction).

Regulatory status

Not addressed in the FDA label.

Population evidence

Ceriello A et al., "Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes," Diabetes Metab Res Rev, 2008, PMID 17694505: human RCT, pramlintide in the cohort. Ceriello A et al., "Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes," Diabetes Care, 2005, PMID 15735200: human RCT, pramlintide in the cohort. Both titles and journal/PMID metadata were confirmed via a dedicated PubMed search-listing page; the individual abstract pages could not be opened this session (persistent bot-verification block), so exact sample sizes, marker names, and effect-size/p-value figures could not be independently verified and are not stated here beyond what the confirmed titles report.

Mechanism

Not independently confirmed this session beyond the titles. Supporting, pramlintide-specific in vitro and disease-model work in the same protective direction: Safaeian L et al., "Pramlintide: An Amylin Analogue Protects Endothelial Cells against Oxidative Stress through Regulating Oxidative Markers and NF-kappab Expression," Int J Prev Med, 2022, PMID 35392304 (human endothelial cell culture); Patrick S et al., "Neuroprotective Effects of the Amylin Analog, Pramlintide, on Alzheimer's Disease Are Associated with Oxidative Stress Regulation Mechanisms," J Alzheimers Dis, 2019, PMID 30958347 (disease-model study). Both confirmed to title/PMID/journal depth only, same access limitation as above.

Counter-evidence held on record

No trial identified showed pramlintide worsening oxidative-stress markers; all four sources located (2 Tier A human trials, 2 Tier B mechanistic/disease-model studies) point the same protective direction. This is a reverse-direction, protective signal, not a depletion or nutrient-loss finding. It is not a basis for any antioxidant-supplement marketing claim, and the precise effect sizes could not be verified this session due to a tooling access limitation (see Sources), so the finding should be treated as directionally supported rather than quantitatively established until the full texts can be reviewed.

Limits on what this shows

• Key negative/null findings: No human or animal study measuring copper status (serum copper, ceruloplasmin) in pramlintide-treated subjects was found in any search performed.
• At-risk subgroups: None established; no human exposure data exist.

Regulatory status

Not addressed in the FDA label.

Population evidence

Alghrably M et al., "Copper(II) and Amylin Analogues: A Complicated Relationship," Inorg Chem, 2020, PMID 32027132: in vitro biophysical/spectroscopic study naming pramlintide specifically, reporting "the N-termini of both peptides are involved in Cu(2+) binding; His18 imidazole is an equally attractive binding site in the case of pramlintide" (confirmed via PubMed search-listing snippet). Dzień E et al., "Thermodynamic surprises of Cu(II)-amylin analogue complexes in membrane mimicking solutions," Sci Rep, 2022, PMID 35013439: in vitro study explicitly naming pramlintide and Ac-pramlintide among the amylin analogues studied (confirmed via PubMed search-listing snippet). Neither paper's full text could be opened this session (persistent bot-verification block); binding stoichiometry and affinity constants beyond the quoted snippet were not independently verified.

Mechanism

Named: direct coordination of Cu(2+) by pramlintide's peptide backbone (N-terminus) and His18 imidazole side chain, characterized by isothermal titration calorimetry, NMR, and related spectroscopic methods in cell-free/membrane-mimicking solutions. This is peptide-metal coordination chemistry, not a demonstrated physiological copper-sequestration or copper-deficiency mechanism in a living organism.

Counter-evidence held on record

No human copper-status study in pramlintide-treated patients was found despite dedicated searches; this is disclosed as an evidence gap on the human-relevance side of this entry, not as reassurance. This is in vitro, cell-free coordination chemistry. It is not evidence that pramlintide depletes or alters copper status in people taking it, and it is not a basis for any copper-supplementation decision.

Limits on what this shows

• Why no grade: Searched via PubMed with multiple phrasings: "pramlintide iron" (0 results), "amylin iron" (16 results reviewed, all concerning endogenous human IAPP amyloid/heme/metal-nanoparticle chemistry unrelated to pramlintide the drug or to physiological iron status), and "pramlintide hemoglobin OR hematocrit OR anemia" (81 results reviewed; every result matched on glycosylated hemoglobin/HbA1c as a glycemic-control outcome measure, not iron-related hemoglobin or iron status). Unlike copper and zinc, no pramlintide-specific metal-binding study naming iron was found. No circulating consumer claim linking pramlintide to iron status was identified. Both conditions required for UNGRADED are met.

Tooling note

These PubMed searches completed successfully (not blocked), so the absence of results reflects a genuine literature gap for this category as searched. Broader verification was limited because the Europe PMC, Semantic Scholar, Crossref, and OpenAlex APIs all returned 429/503 errors on every attempt this session, and the WebSearch tool's budget was already exhausted; a future revision should re-check this category once those channels are available.

Limits on what this shows

• Why no grade: Searched via PubMed with multiple phrasings: "pramlintide gut microbiome OR pramlintide microbiota" (blocked by bot verification on first attempt, retried), "pramlintide microbiome" (0 results), "pramlintide microbiota" (0 results), and "amylin gut microbiota" (14 results reviewed; all were false-positive keyword matches, most from studies using the "Gubra-Amylin NASH" (GAN) diet, a named rodent diet formulation for liver-disease modeling unrelated to the amylin hormone or pramlintide the drug). No genuine pramlintide-specific or amylin-hormone-specific microbiome study was found. Pramlintide is the sole FDA-approved amylin analog, so no other class member exists to extrapolate a yellow grade from. No circulating consumer claim was identified, though this session's ability to audit consumer content was itself limited (see tooling note). Both conditions required for UNGRADED are met on the literature side.

Tooling note

The completed PubMed searches returned genuine (if false-positive) results, so this reflects a real literature gap for pramlintide and gut microbiome as searched. The WebSearch tool's session budget was exhausted before this review began, and both Bing and DuckDuckGo refused automated access under robots.txt, so the "no circulating claim" half of this determination could not be independently verified against general consumer web content this session; a future revision with WebSearch access should re-check specifically for a circulating microbiome claim.

Limits on what this shows

• Why no grade: Searched via PubMed: "pramlintide hemoglobin OR pramlintide hematocrit OR pramlintide anemia" returned 81 results, all of which matched on glycosylated hemoglobin (HbA1c) as a glycemic-control efficacy outcome across pramlintide's clinical-trial literature, not on oxygen-carrying hemoglobin, hematocrit, red-cell mass, or arterial oxygenation. No result addressed oxygen delivery or utilization in any form. No circulating consumer claim linking pramlintide to oxygen-carrying capacity was identified. Both conditions required for UNGRADED are met.

Tooling note

This search completed successfully and returned a large, reviewable result set, so the absence of a relevant hit is a genuine finding rather than a blocked search. Cross-checking against Europe PMC, Semantic Scholar, Crossref, and OpenAlex was not possible this session (429/503 errors on every attempt); a future revision should re-check this category once those channels are available.

Limits on what this shows

• Why no grade: Searched via PubMed: "pramlintide ATP" returned 0 results. "pramlintide energy expenditure" returned 36 results; these consistently described amylin/pramlintide's established, whole-body physiological role in increasing energy expenditure and promoting satiety as part of its intended glucoregulatory and weight-management pharmacology (for example, a 2025 review stating pramlintide's actions include "increasing energy expenditure and promoting satiety"). Per protocol, a drug's own intended pharmacologic effect on systemic energy balance is not filed as a cellular ATP-production/mitochondrial-energetics finding, so this body of evidence was deliberately excluded rather than used to support a grade. No study measuring mitochondrial ATP synthesis or cellular ATP levels specifically in the context of pramlintide was found. No circulating consumer claim was identified. Both conditions required for UNGRADED are met.

Tooling note

Both searches completed successfully. The Europe PMC, Semantic Scholar, Crossref, and OpenAlex APIs could not be reached this session (429/503 errors on every attempt) to cross-check for a cell-level ATP study that PubMed's own index might have missed; a future revision should re-check this category once those channels are available.